
About
Microbot Medical is dedicated to delivering transformative interventional robotic solutions that prioritize patient care, empower healthcare providers, and enable access to advanced care anytime and anywhere. The company is pioneering a new category of surgical robotics with its LIBERTY Endovascular Robotic System, which aims to redefine medical technology's role in empowering healthcare professionals and enhancing accessibility for all stakeholders. The mission is driven by a patient-first mindset, collaboration, and a sense of responsibility to those they serve.
Verified company data
- Shares outstanding
- 45,545,939
- Fully diluted shares
- 81,846,616
- Projects
LIBERTY® Endovascular Robotic System
Performance Meets Precision
Step into the next generation of endovascular intervention. LIBERTY® is engineered for physicians who demand control, efficiency and peace of mind.
Test Drive LIBERTY™
Robotic Drive
Remote Control
Mounting Arm
Drive the Future of Intervention™
LIBERTY® delivers smooth, responsive peripheral endovascular navigation in a single-use, remotely operated design that fits seamlessly into your workflow. You are in command, even from across the room.
Test Drive LIBERTY™
A New Era in Endovascular Care
Unlike traditional manual techniques, LIBERTY Endovascular Robotic System offers a single-use, compact solution that enables controlled remote operation while transforming vascular access and navigation without the complexity or cost of capital equipment.
No Large Capital Investment
Single-use without need for capital investment.
Reduce Radiation Exposure
92% reduction in radiation exposure.1,2
Compact Design
Compact system integrates effortlessly into your existing workflow.
Control and Comfort
Remote, seated operation enables improved ergonomics.
Efficient Set-Up
Simple and intuitive setup in under 5 minutes.¹
Universal Compatibility
Compatible with your preferred guidewires and catheters.
AccuGrip™
AccuGrip™ securely holds wires and catheters
Download LIBERTY® Brochure
Intended Use and Indications for Use:
The LIBERTY Endovascular Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters to facilitate navigation to anatomical targets in the peripheral vasculature.
The LIBERTY Endovascular Robotic System is not intended for coronary or neurointerventional procedures.
1Abstract No. LBA15 Remote-Controlled Endovascular Navigation with a Miniature, Single-Use, Robotic System. Results of the ACCESS-PVI Trial Cornelis, F. et al. Journal of Vascular and Interventional Radiology, Volume 36, Issue 3, S235 – S236
2Data on file
3Research report from wet-lab with nine experienced interventional radiologists. Set-up times and learning curve will vary with user
*Within the product specifications
LIBERTY was designed to address the growing unmet needs in healthcare impacting physicians, hospitals, and patients.
Radiation & Ergonomic Risks1
Interventionalists have:
6× higher risk of cataracts
3× higher risk of malignancyErgonomic / Musculoskeletal Risks:
66% reported musculoskeletal pain related to wearing lead protective equipment
60% reported at least one orthopedic injuryStaff Shortage
IR is ranked 2nd in specialties facing the greatest physician shortages2
Healthcare faces staff shortages of 85K+ by 20363
Nearly 50% of physicians report burnout3
1 in 5 physicians report experiencing depression, exacerbating workforce gaps3Access to Quality Care4
20% of Americans live in rural areas where only 10% of doctors practice
80% of rural Americans are medically underserved
~200 rural hospitals have closed since 2005Family Planning5
28% of women respondents reported being discouraged from working in the Cath lab due to pregnancy or considering pregnancy.
71% of women respondents said they wanted the option to step away from the Cath lab during pregnancy.Sources
3 https://nihcm.org/newsletter/rising-healthcare-workforce-shortage
4 https://nihcm.org/publications/rural-health-needs-in-america-challenges-and-solutions
- Leadership
Harel Gadot (CEO, President and Chairman), Simon Sharon (GM, Chief Technology Officer), Rachel Vaknin (Chief Financial Officer), Juan Diaz-Cartelle, MD (Chief Medical Officer), Earl Adamy (VP, Strategic Marketing & Business Development), Christina Bailey (VP, Sales), Eran Cohen (VP, Global Integration), Naama Moav (VP, Human Resources), Noa Ofer, PhD (VP, Quality Assurance and Regulatory Affairs), Allison Rosefort (VP, Marketing), Alon Tamir (VP, Sales, EMEA), Martin J. Madden (Director), Scott Burell (Director), Aileen Stockburger (Director), P. Laxminarain (Director), Tal Wenderow (Director), David Wilson (Director)
Verified data last updated:
Recent filings
- Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements · Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements (QuoteMedia 7501507287081693)
- Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion · Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion (QuoteMedia 4550003857150999)
- Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026 · Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026 (QuoteMedia 7466343605645458)
Investor FAQ
The most recent item in the document index is a press release dated 2026-11-16 announcing that Microbot Medical filed its 10-Q and highlighted key third quarter operating achievements. Earlier, on 2026-11-05, the company announced it strengthened its IP portfolio as it continues to establish infrastructure to support future commercialization expansion. The company's index also includes a 2026-05-14 press release reporting that it successfully transitioned to commercial operations and recorded revenue from its limited market release during the first quarter of 2026.
- Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements ·
- Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion ·
- Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026 ·
Not disclosed in available filings. The available documents describe the 10-Q filing and third quarter operating achievements, IP portfolio strengthening, and the transition to commercial operations with revenue from a limited market release, but do not specify dated upcoming events or milestones.
- Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements ·
- Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion ·
- Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026 ·
Answers last refreshed: